Proinsulin C-peptide
EstablishedC-peptide distinguishes endogenous from injected insulin sources and helps classify diabetes type.
C-peptide is released alongside the body's own insulin, but not with injected insulin, making it useful for figuring out whether high insulin levels are coming from the body itself (like from a rare tumor) or from an outside source. It's also used to help classify diabetes type.
C-peptide is a byproduct released in equal amounts to insulin when the pancreas processes proinsulin into active insulin, making it a useful marker of the body's own (endogenous) insulin production, distinct from injected insulin.
C-peptide, measured alongside insulin and glucose, is central to diagnosing insulinoma and distinguishing genuine endogenous hyperinsulinism from factitious (self-induced) hypoglycemia, since commercially injected insulin doesn't contain C-peptide.
Measured as part of the 72-hour (or shortened 48-hour) supervised fasting test alongside glucose, insulin, and proinsulin; an insulin-to-C-peptide ratio below 1 supports insulinoma, while a ratio above 1 in the presence of hypoglycemia suggests factitious insulin administration.
C-peptide is also used more broadly in diabetes classification, helping distinguish type 1 diabetes (low/absent C-peptide, indicating little remaining endogenous insulin production) from type 2 diabetes (typically preserved or even elevated C-peptide, reflecting insulin resistance).
Central to the insulin-to-C-peptide ratio used in diagnosing insulinoma versus factitious hypoglycemia.
- StatPearls. (2025). Insulinoma.
- General endocrinology reference literature on C-peptide in diabetes classification.